Sergio L. Santillana
2017
In 2017, Sergio L. Santillana earned a total compensation of $652.3K as Chief Medical Officer at Merrimack Pharmaceuticals.
Compensation breakdown
| Non-Equity Incentive Plan | $87,596 |
|---|---|
| Option Awards | $355,815 |
| Salary | $201,923 |
| Other | $6,927 |
| Total | $652,261 |
Santillana received $355.8K in option awards, accounting for 55% of the total pay in 2017.
Santillana also received $87.6K in non-equity incentive plan, $201.9K in salary and $6.9K in other compensation.
Rankings
In 2017, Sergio L. Santillana's compensation ranked 10,888th out of 14,666 executives tracked by ExecPay. In other words, Santillana earned more than 25.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 10,888 out of 14,666 | 26th |
Division Manufacturing | 4,248 out of 5,772 | 26th |
Major group Chemicals And Allied Products | 1,523 out of 2,075 | 27th |
Industry group Drugs | 1,247 out of 1,731 | 28th |
Industry Pharmaceutical Preparations | 970 out of 1,333 | 27th |
Source: SEC filing on April 27, 2018.
Santillana's colleagues
We found six more compensation records of executives who worked with Sergio L. Santillana at Merrimack Pharmaceuticals in 2017.
2017
Richard Peters
Merrimack Pharmaceuticals
Chief Executive Officer
2017
Jeffrey Munsie
Merrimack Pharmaceuticals
General Counsel
2017
Daryl Drummond
Merrimack Pharmaceuticals
Head of Research
2017
Jean Franchi
Merrimack Pharmaceuticals
Chief Financial Officer
2017
Yasir Al-Wakeel
Merrimack Pharmaceuticals
Chief Financial Officer
2017
Gary Crocker
Merrimack Pharmaceuticals